| Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial A Sabchareon, D Wallace, C Sirivichayakul, K Limkittikul, ... The Lancet 380 (9853), 1559-1567, 2012 | 988 | 2012 |
| From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine B Guy, B Barrere, C Malinowski, M Saville, R Teyssou, J Lang Vaccine 29 (42), 7229-7241, 2011 | 420 | 2011 |
| Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses B Guy, F Guirakhoo, V Barban, S Higgs, TP Monath, J Lang Vaccine 28 (3), 632-649, 2010 | 337 | 2010 |
| Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates F Guirakhoo, K Pugachev, Z Zhang, G Myers, I Levenbook, K Draper, ... Journal of virology 78 (9), 4761-4775, 2004 | 331 | 2004 |
| Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses. A Sabchareon, J Lang, P Chanthavanich, S Yoksan, P Attanath, ... The American journal of tropical medicine and hygiene 66 (3), 264-272, 2002 | 261 | 2002 |
| Treatment of severe colchicine overdose with colchicine-specific Fab fragments FJ Baud, A Sabouraud, E Vicaut, P Taboulet, J Lang, C Bismuth, ... New England Journal of Medicine 332 (10), 642-645, 1995 | 260 | 1995 |
| Live attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in … F Guirakhoo, S Kitchener, D Morrison, R Forrat, K McCarthy, R Nichols, ... Human vaccines 2 (2), 60-67, 2006 | 257 | 2006 |
| A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes in Flavivirus-Naive Adults D Morrison, TJ Legg, CW Billings, R Forrat, S Yoksan, J Lang The Journal of infectious diseases 201 (3), 370-377, 2010 | 227 | 2010 |
| Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward B Guy, O Briand, J Lang, M Saville, N Jackson Vaccine 33 (50), 7100-7111, 2015 | 195 | 2015 |
| Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five-to twelve-year-old Thai children A Sabchareon, J Lang, P Chanthavanich, S Yoksan, R Forrat, P Attanath, ... The Pediatric infectious disease journal 23 (2), 99-109, 2004 | 193 | 2004 |
| Development of Sanofi Pasteur tetravalent dengue vaccine B Guy, M Saville, J Lang Human vaccines 6 (9), 696-705, 2010 | 178 | 2010 |
| Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults S Kitchener, M Nissen, P Nasveld, R Forrat, S Yoksan, J Lang, JF Saluzzo Vaccine 24 (9), 1238-1241, 2006 | 174 | 2006 |
| Evaluation of interferences between dengue vaccine serotypes in a monkey model B Guy, V Barban, N Mantel, M Aguirre, S Gulia, J Pontvianne, TM Jourdier, ... American Journal of Tropical Medicine and Hygiene 80 (2), 302, 2009 | 173 | 2009 |
| Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines RZ Capeding, IA Luna, E Bomasang, S Lupisan, J Lang, R Forrat, ... Vaccine 29 (22), 3863-3872, 2011 | 164 | 2011 |
| Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects B Guy, N Nougarede, S Begue, V Sanchez, N Souag, M Carre, ... Vaccine 26 (45), 5712-5721, 2008 | 158 | 2008 |
| Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy A Strady, J Lang, M Lienard, C Blondeau, R Jaussaud, SA Plotkin The Journal of infectious diseases 177 (5), 1290-1295, 1998 | 136 | 1998 |
| Live-attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity J Poo, F Galan, R Forrat, B Zambrano, J Lang, GH Dayan The Pediatric infectious disease journal 30 (1), e9-e17, 2011 | 134 | 2011 |
| Comparison of the immunogenicity and safety of two 17D yellow fever vaccines. J Lang, J Zuckerman, P Clarke, P Barrett, C Kirkpatrick, C Blondeau The American journal of tropical medicine and hygiene 60 (6), 1045-1050, 1999 | 109 | 1999 |
| Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3) V Sanchez, S Gimenez, B Tomlinson, PKS Chan, GN Thomas, R Forrat, ... Vaccine 24 (23), 4914-4926, 2006 | 101 | 2006 |
| Clinical safety of a polyvalent F (ab′) 2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon JP Chippaux, J Lang, SA Eddine, P Fagot, V Rage, JC Peyrieux, ... Transactions of the Royal Society of Tropical Medicine and Hygiene 92 (6 …, 1998 | 101 | 1998 |
